Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 6.

Dietz, Julia; Susser, Simone; Vermehren, Johannes; Peiffer, Kai-Henrik; Grammatikos, Georgios; Berger, Annemarie; Ferenci, Peter; Buti, Maria; Müllhaupt, Beat; Hunyady, Bela; Hinrichsen, Holger; Mauss, Stefan; Petersen, Jörg; Buggisch, Peter; Felten, Gisela; Hüppe, Dietrich; Knecht, Gaby; Lutz, Thomas; Schott, Eckart; Berg, Christoph; Spengler, Ulrich; von Hahn, Thomas; Berg, Thomas; Zeuzem, Stefan; Sarrazin, Christoph; European HCV Resistance Study Group (2018). Patterns of Resistance-associated Substitutions in Patients With Chronic HCV Infection Following Treatment with Direct-acting Antivirals. Gastroenterology, 154(4):976-988.e4.

Lawitz, Eric; Buti, Maria; Vierling, John M; Almasio, Piero L; Bruno, Savino; Ruane, Peter J; Hassanein, Tarek I; Muellhaupt, Beat; Pearlman, Brian; Jancoriene, Ligita; Gao, Wei; Huang, Hsueh-Cheng; Shepherd, Aimee; Tannenbaum, Brynne; Fernsler, Doreen; Li, Jerry J; Grandhi, Anjana; Liu, Hong; Su, Feng-Hsiu; Wan, Shuyan; Dutko, Frank J; Nguyen, Bach-Yen T; Wahl, Janice; Robertson, Michael N; Barr, Eliav; Yeh, Wendy W; Plank, Rebeca M; Butterton, Joan R; Yoshida, Eric M (2017). Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. Lancet Gastroenterology & Hepatology, 2(11):814-823.

Manns, Michael; Samuel, Didier; Gane, Edward J; Mutimer, David; McCaughan, Geoff; Buti, Maria; Prieto, Martín; Calleja, José Luis; Peck-Radosavljevic, Markus; Müllhaupt, Beat; Agarwal, Kosh; Angus, Peter; Yoshida, Eric M; Colombo, Massimo; Rizzetto, Mario; Dvory-Sobol, Hadas; Denning, Jill; Arterburn, Sarah; Pang, Phillip S; Brainard, Diana; McHutchison, John G; Dufour, Jean-François; Van Vlierberghe, Hans; van Hoek, Bart; Forns, Xavier; SOLAR-2 investigators (2016). Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infectious Diseases, 16(6):685-697.

Zeuzem, Stefan; Soriano, Vicente; Asselah, Tarik; Gane, Edward J; Bronowicki, Jean-Pierre; Angus, Peter; Lohse, Ansgar W; Stickel, Felix; Müllhaupt, Beat; Roberts, Stuart; Schuchmann, Marcus; Manns, Michael; Bourlière, Marc; Buti, Maria; Stern, Jerry O; Gallivan, John-Paul; Voss, Florian; Sabo, John P; Böcher, Wulf; Mensa, Federico J (2015). Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis. Antimicrobial Agents and Chemotherapy, 59(2):1282-1291.

Asselah, Tarik; Zeuzem, Stefan; Soriano, Vicente; Bronowicki, Jean-Pierre; Lohse, Ansgar W; Müllhaupt, Beat; Schuchmann, Marcus; Bourlière, Marc; Buti, Maria; Roberts, Stuart K; Gane, Edward J; Stern, Jerry O; Voss, Florian; Baum, Patrick; Gallivan, John-Paul; Böcher, Wulf O; Mensa, Federico J (2015). ITPA genotypes predict anemia but do not affect virological response with interferon-free faldaprevir, deleobuvir, and ribavirin for hcv infection. PLoS ONE, 10(12):e0144004.

Zeuzem, Stefan; Soriano, Vincent; Asselah, Tarik; Bronowicki, Jean-Pierre; Lohse, Ansgar W; Müllhaupt, Beat; Schuchmann, Marcus; Bourlière, Marc; Buti, Maria; Roberts, Stuart K; Gane, Ed J; Stern, Jerry O; Vinisko, Richard; Kukolj, George; Gallivan, John-Paul; Böcher, Wulf-Otto; Mensa, Federico J (2013). Faldaprevir and deleobuvir for HCV genotype 1 infection. New England Journal of Medicine, 369(7):630-639.

This list was generated on Mon Sep 24 21:13:47 2018 CEST.